Bioheng Therapeutics Receives FDA RPDD for Off‑The‑Shelf CAR‑T CTD402
Bioheng Therapeutics (China) announced that the U.S. Food and Drug Administration (FDA) has granted Rare...
JCBio & MGI Launch Korea’s First DCS Lab to Accelerate Multi‑Omics Innovation
South Korean biotechnology firm JCBio and global genomics leader MGI Tech Co., Ltd. today signed...
IVD Medical Acquires 20 % of GoFintech in HK$3.14 B Deal
IVD Medical Holding Limited (HKG: 1931) disclosed that it will purchase 1,848,496,429 shares of GoFintech...
Fosun Pharma Secures China Rights to Accropeutics’ AC‑201 JAK Inhibitor
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that it has...
Shenlian Bio Launches Phase 2 Trial for UB‑221 Injection in Chronic Urticaria
Shanghai Shenlian Biomedical Co., Ltd. (Shenlian Bio, SHA: 688098) announced that its licensed innovative drug,...
Mabwell’s 9MW3811 Receives NMPA Phase II Approval for Pathological Scar Treatment
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced on September 1 that the National Medical...
Suzhou Zelgen Secures FDA Approval for Dual‑Targeted Therapy Trial in Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the U.S. Food and Drug Administration...
Mabwell Secures First Overseas Approval for Denosumab Biosimilars in Pakistan
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the Drug Regulatory Authority of Pakistan...
Novo Nordisk’s STEER Study: Wegovy Cuts Cardiovascular Risk 57 % vs. Tirzepatide
Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) presented compelling real‑world evidence from the STEER...
Eisai & Biogen Secure FDA Approval for Lecanemab Auto‑Injector – Home‑Based Alzheimer’s Therapy
Japan-based Eisai (TYO: 4523) and US-based Biogen (NASDAQ: BIIB) announced that the U.S. Food and...
PackGene & CMRI Announce AAV Screening Kit for Global Gene Therapy R&D
PackGene LLC, a global leader in gene‑therapy contract development and manufacturing, and the Children’s Medical...
Suzhou HemaCell Receives NMPA IND Approval for First‑In‑Class Megakaryocyte Injection – Thrombocytopenia Treatment
Suzhou HemaCell Therapeutics, a platelet‑regeneration‑focused cell‑therapy developer, announced that the Center for Drug Evaluation (CDE)...
Everest Medicines Reports 48 % YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone
Everest Medicines Limited (HKG: 1952) released unaudited interim financial results for the six months ended...
Luye Pharma Reports 1H 2025 Revenue Growth of 3.5 % Amid Oncology and CNS Gains
Luye Pharma Group Ltd. (HKG: 2186) on Aug. 28, 2025 released its financial performance for...
Shanghai Pharma Reports 2025 Interim Results: 1.6% Revenue Rise, 41% Profit Surge
Shanghai Pharmaceutical Holding Co., Ltd. (SHA: 601607, HKG: 2607) on Aug. 28, 2025 announced its...
Zennova & Rapafusyn Forge BioCarier‑Powered RapaGlue Collaboration – 2025
Zennova Pharmaceuticals Group and Rapafusyn Pharmaceuticals on Aug. 28, 2025 announced a strategic collaboration to...
Boehringer Ingelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China
In a joint announcement, Boehringer Ingelheim (BI) and Sino Biopharmaceutical Limited (HKG: 1177) confirmed that the...
Innovent Biologics Revenue Soars 50% in H1 2025 – Oncology Growth Fuels GLP‑1 Expansion
China-based Innovent Biologics, Inc. (HKG: 1801) on Aug. 28, 2025 released its semi‑annual financial results for...
NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed
The National Healthcare Security Administration (NHSA) on Aug. 28, 2025 announced the formal review outcomes...
HarbourBioMed Reports 327 % Revenue Surge, Launches HCAb‑Based Élancé Therapeutics
Harbour BioMed (HKG: 2142) on Aug. 27, 20025 released its first‑half 2025 financial results, reporting...